Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer

Phase 2 Terminated 5 enrolled National Cancer Institute (NCI)

NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well savolitinib works in treating patients with MET amplified colorectal cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Savolitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start: 2019-07-25
Primary completion: 2021-07-31
Completion: 2021-12-30

Outcome

Missed primary endpoint

Stopped (Enrollment): “Inadequate accrual rate”

paper Best overall response was stable disease (SD) in two patients, progressive disease (PD) in two patients, and one patient unevaluable for response. PMID 39652198 ↗

paper we observed no evidence of anti-tumor activity. PMID 39652198 ↗

Publications

Jia J, Moyer A, Lowe M, Bolch E, Kortmansky J, Cho M, Lenz HJ, Kalyan A, Niedzwiecki D, Strickler JH. A Phase 2 study of Savolitinib in Patients with MET Amplified Metastatic Colorectal Cancer. J Gastrointest Cancer. 2024 Dec 9;56(1):29. doi: 10.1007/s12029-024-01156-x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Savolitinib	Small molecule	—	Oral